2016 Press Releases

2016 Press Releases

2017 | 2016 | 2015 | 2014
Reata Pharmaceuticals, Inc. Announces Requested Withdrawal of Registration Statement Due to Adverse Market Conditions
Reata Pharmaceuticals, Inc. Announces Filing of Registration Statement for Proposed Public Offering
Reata Announces Plan for Global Phase 2/3 Trial in Chronic Kidney Disease Caused by Alport Syndrome
Reata Pharmaceuticals, Inc. Announces Third Quarter 2016 Financial and Operating Results
Reata Pharmaceuticals, Inc. Appoints Dawn Carter Bir as Vice President and Chief Commercial Officer
Reata Enrolls First Patient in Phase 3 CATALYST Trial of Bardoxolone Methyl in CTD-PAH Patients and Reports Positive Interim Data From CTD-PAH Patients in Phase 2 LARIAT Trial
Reata Pharmaceuticals, Inc. Announces Second Quarter 2016 Financial and Operating Results
Reata Pharmaceuticals, Inc. Announces Interim Data From Extension Phase 2 LARIAT Study in Pulmonary Arterial Hypertension
Reata Pharmaceuticals, Inc. Announces Closing of Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares of Class A Common Stock
Reata Pharmaceuticals, Inc. Announces Pricing of Initial Public Offering
Reata Enrolls First Patient with Pulmonary Hypertension Associated with Interstitial Lung Disease in LARIAT, a Phase 2 Study Examining Bardoxolone Methyl for the Treatment of Patients with Pulmonary Hypertension